PTHS
Pelthos Therapeutics Inc.
Key Financials
Revenue
$16.8M
↑ Infinity%
Operating Income
$-32430000
↓ 328.3%
Net Income
$-43319000
↓ 444.5%
Total Assets
$130.4M
↑ 9424.0%
EPS (Diluted)
$-23.04
↓ 1511.2%
Shareholders' Equity
$38.9M
↑ 1532.6%
Total Liabilities
$91.5M
↑ 2141.3%
Cash & Equivalents
$18.0M
↑ 3403.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 8/13/2026 | View on SEC |
| 8-K | 8/13/2026 | View on SEC |
| 10-Q/A | 8/13/2026 | View on SEC |
| 8-K | 8/13/2026 | View on SEC |
| PRE 14A | 8/7/2026 | View on SEC |
| 4 | 7/7/2026 | View on SEC |
| 4 | 7/7/2026 | View on SEC |
| 4 | 7/7/2026 | View on SEC |
| 4 | 6/17/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | PTHS |
| Company Name | Pelthos Therapeutics Inc. |
| CIK | 1919246 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | NYSE |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | NV |
| Phone | 919-908-2422 |